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Simple Summary: It is well-recognised the strong contribution of genetic factors to prostate cancer
(PrCa) susceptibility, thus genetic screening is critical for presymptomatic diagnosis and identification
of individuals at high-risk. In this context, recurrent founder variants in cancer predisposing genes,
by providing specific targets for early identification of carriers at risk of developing the disease, may be
leveraged to implement cost-efficient targeted genetic screening strategies. The goal of this study was
to investigate whether CHEK2 c.349A>G, the only recurrent “likely pathogenic” variant in CHEK2
gene reported in the Portuguese population, plays an important role in PrCa development, and the
possibility of a founder effect behind its origin. Our results clearly demonstrate that c.349A>G in the
CHEK2 tumour-suppressor gene is a founder variant significantly associated with an increased risk of
PrCa, suggesting its potential usefulness for cost-effective targeted genetic screening in PrCa families.
Abstract: The identification of recurrent founder variants in cancer predisposing genes may have
important implications for implementing cost-effective targeted genetic screening strategies. In this
study, we evaluated the prevalence and relative risk of the CHEK2 recurrent variant c.349A>G in a
series of 462 Portuguese patients with early-onset and/or familial/hereditary prostate cancer (PrCa),
as well as in the large multicentre PRACTICAL case–control study comprising 55,162 prostate cancer
cases and 36,147 controls. Additionally, we investigated the potential shared ancestry of the carriers
by performing identity-by-descent, haplotype and age estimation analyses using high-density SNP
data from 70 variant carriers belonging to 11 different populations included in the PRACTICAL
consortium. The CHEK2 missense variant c.349A>G was found significantly associated with an
increased risk for PrCa (OR 1.9; 95% CI: 1.1–3.2). A shared haplotype flanking the variant in all
carriers was identified, strongly suggesting a common founder of European origin. Additionally,
using two independent statistical algorithms, implemented by DMLE+2.3 and ESTIAGE, we were
able to estimate the age of the variant between 2300 and 3125 years. By extending the haplotype
analysis to 14 additional carrier families, a shared core haplotype was revealed among all carriers
matching the conserved region previously identified in the high-density SNP analysis. These findings
are consistent with CHEK2 c.349A>G being a founder variant associated with increased PrCa risk,
suggesting its potential usefulness for cost-effective targeted genetic screening in PrCa families.
Keywords: prostate cancer; founder variant; CHEK2; cancer predisposition
1. Introduction
Prostate cancer (PrCa) is one of the most commonly diagnosed cancers worldwide, representing
the second leading cause of cancer mortality among men in the developed countries [1]. Despite the
strong epidemiological evidence supporting a genetic contribution to PrCa, with 10–20% of the cases
expected to occur in a hereditary/familial context, the genetic aetiology is still largely unknown [2].
To date, numerous family-based linkage and genome-wide association studies (GWAS) have reported
more than 100 common low-penetrance genetic variants associated with PrCa risk, most of which were
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identified in populations of European ancestry [3–8]. However, no specific high-risk gene for PrCa
has been identified. Apart from some well-established moderate-risk genes [9–17], a few additional
candidate genes have, more recently, been proposed to explain PrCa heritability.
CHEK2 is a tumour suppressor gene that encodes a serine threonine kinase involved in pathways
such as DNA repair, cell cycle arrest, mitosis, and apoptosis [18–20]. Although several germline variants
in the CHEK2 gene have been associated with increased cancer risk, the knowledge regarding the full
mutational spectra and specific variant-associated risk, particularity in PrCa, is still limited [21]. So far,
the c.1100delC and p.I157T CHEK2 variants are the most comprehensively studied, being associated in
large case–control studies with increased risk for different types of cancer, such as testicular germ cell
tumours, breast and colorectal cancers [22–24]. Other cancer risk-associated CHEK2 variants have been
reported [22], some of which in ethnically defined groups such as the Ashkenazi Jewish population [25],
suggesting the influence of founder effects underlying CHEK2 mutational spectra.
Recently, we performed a comprehensive genetic screening of 94 genes associated with inherited
cancer predisposition in a selected series of 121 Portuguese patients with early-onset disease and/or
criteria for familial/hereditary PrCa [26]. Only one recurrent variant, namely CHEK2 c.349A>G,
was identified in two Portuguese PrCa families. This variant, classified as “pathogenic/likely
pathogenic” by ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/, accessed in January 2020), has already
been implicated in previous large-scale studies with increased risk for breast cancer (BrCa), but not
PrCa development [22]. The existence of a recurrent “likely pathogenic” variant in the CHEK2 gene
may be the reflection of a founder event. The identification of founder variants in cancer predisposing
genes is important to improve risk assessment in specific populations, allowing more cost-efficient
screening strategies by providing specific targets for early identification of carriers at risk to develop the
disease. It remains unknown whether the CHEK2 variant c.349A>G may have arisen from a common
founder ancestor or independently through time.
In this work, we aimed to further explore the relevance of the CHEK2 variant c.349A>G in
early-onset/familial PrCa, by evaluating its prevalence in a series of 462 Portuguese PrCa patients with
early-onset disease and/or criteria for familial/hereditary PrCa [27]. Additionally, we aimed to explore
the hypothesis of a possible founder effect in the origin of this CHEK2 variant by performing haplotype
and age estimation analyses in PrCa patients and controls from 11 different populations included in
the PRATICAL (Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the
Genome) consortium.
2. Results
2.1. Frequency of the CHEK2 Variant c.349A>G
To evaluate the previously suggested contribution of CHEK2 variant c.349A>G to early-onset and/
or familial PrCa risk, we screened a series of 462 early-onset/familial PrCa cases and compared the
frequency in cases with that previously obtained for 710 controls. In addition to the two PrCa cases
previously reported [26], the c.349A>G variant was found in three PrCa cases, corroborating a higher
frequency in cases (n = 5) comparing with controls (n = 1), rendering a borderline association with
increased risk of PrCa (OR 7.7; 95% CI: 0.9–66.6; p = 0.06).
To further investigate the possible association with increased PrCa risk, we increased the statistical
power by evaluating the frequency of the CHEK2 variant c.349A>G among the 91,309 individuals
available from the PRATICAL consortium. The variant was found in 52 PrCa cases (including the four
of the five patients previously identified in the Portuguese early-onset and/or hereditary PrCa series)
and 18 heathy controls belonging to 11 worldwide spread populations of European ancestry (Table S1),
corroborating the association with PrCa (OR 1.9; 95% CI: 1.1–3.2; p = 0.04) hinted by the analysis of the
Portuguese early-onset/familial PrCa series.
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2.2. Identification of IBD Haplotype and Phylogeographic Analysis
The identity-by-descent (IBD) analysis of the high-density SNP data from chromosome 22 revealed
the existence of a shared haplotype with different lengths flanking the CHEK2 variant c.349A>G among
all the 70 variant carriers from the different populations. As presented in Figure 1A, a conserved
variant haplotype of ≈1 Mb (chr22: 28,374,461–29,327,347) was found in most of the populations.
Noteworthy, we grouped the carriers from France, Germany, Netherlands, and Belgium into a single
Western/Central European group, as well as the ones from Denmark and Sweden into a Scandinavian
group, due to population size limitations. Interestingly, the Scandinavian carriers revealed the largest
conserved haplotype, whereas the UK carriers presented a considerably smaller core haplotype
(≈0.4 Mb, chr22: 28,795,304–29,182,169), compared to the other populations. This smaller haplotype
consists of 15 common SNPs featured in the OncoArray DNA chip, in addition to the rare CHEK2
variant c.349A>G (Figure 1B).Cancers 2020, 12, x FOR PEER REVIEW 7 of 18 
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The median-joining phylogenetic tree of the largest identified haplotype (≈1.5 Mb, chr22:
28,170,166–29,620,564) flanking the CHEK2 variant c.349A>G was also consistent with the IBD
analysis, and revealed the existence of two major haplotypes shared by most of the populations
(Figure 1C).
2.3. Age Estimation of the CHEK2 Variant c.349A>G
As the haplotype analysis suggested a founder ancestor among the carriers of the CHEK2 variant
c.349A>G, we sought to estimate its age to obtain further insights regarding its origin and dissemination.
A summary of these results is shown in Tables S2 and S3.
According to DMLE+2.3, the common ancestor of all carriers of the variant originated between
92 (95% CI: 78–118) and 113 (95% CI: 97–145) generations ago, which, considering generations of
25 years, translates into between 2300 and 2825 years ago (Figure 2, Table S2). For comparison, we used
a different statistical approach based on a maximum likelihood algorithm employed by ESTIAGE.
This analysis provided slightly older range estimates, suggesting that the variant arose approximately
123 (95% CI: 104–146) to 125 (95% CI: 106–148) generations ago, that is, 3075–3125 years ago assuming
the 25-year generation time (Table S2).Cancers 2020, 12, x FOR PEER REVIEW 8 of 18 
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To enlighten the dispersal patterns of the CHEK2 variant c.349A>G, we also obtained age estimates
for the different populations separately, using DMLE+2.3 (Table S3, Figures S1–S7). However, due to
sample size limitations, and to be consistent with the haplotype and phylogeographic analysis,
we estimated the variant age in the Western/Central European populations as a group (Belgium, France,
Germany and Netherlands), as well in the Scandinavian populations (Denmark and Sweden).
According to the results, the variant appears to have arisen first in the Western/Central region,
between 81 (95% CI: 65–104) and 100 (95% CI: 81–132) generations ago, that is, between 2015 and
2500 years ago, assuming a 25-year generation time. Later, dispersed through Spain and Portugal around
61–73 and 53–61 generations ago, respectively, corresponding to the variant dating approximately
1525–1825 years in Spain and 1325–1525 years in Portugal. Slightly younger age estimates were obtained
for the UK and Scandinavian carriers, suggesting a common ancestor dating 33 (95% CI: 27–44) to 54
(95% CI: 43–71) generations ago, i.e., 825–1350 years ago, for the first, and dating 42 (95% CI: 31–59) to
49 (95% CI: 38–70) generations ago for the latter, which equates roughly to 1050–1225 years ago.
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Lastly, DMLE+2.3 estimates suggest that the CHEK2 variant c.349A>G was introduced more
recently to the Australian and U.S. populations. The results revealed a common ancestor dating
between 18 (95% CI: 13–24) and 27 (95% CI: 21–38) generations ago among the Australian carriers
and dating between 16 (14–21) and 23 (20–29) generations ago among the US. carriers. Therefore,
the common ancestor of those two populations arose approximately between 450 and 675 years ago,
and between 400 and 575 years ago, respectively (Figure 3).
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Fig re 3. Possible geographic dispersal scenario inferred from present data of the populations carrying
CHEK2 variant c.349A>G, with the average age estimates obtained by DMLE+2.3, using the two
population growth rates. Background map adapted from the map outline published under the terms of
the GNU Free Documentation License, Version 1.2 [28].
2.4. Haplotype Analysis Using Microsatellites
To further extend the haplotype analysis to additional variant carriers from IPO-Porto,
five informative microsatellites markers were analysed on 14 probands with history of prostate,
breast, gastric, and lung cancer, and on the 18 additional family members available.
Consistent with the high-density SNPs haplotype findings, the microsatellite analysis also
identified a common haplotype of different lengths among all carriers of the variant (Table 1). All five
informative families with the c.349A>G variant shared a common haplotype between markers D22S689
and D22S275, spanning a conserved region of approximately of ≈282 Kb. The same haplotype was
compatible with the observed genotypes of the nine remaining probands for which the haplotype phase
could not be explored, due to the lack of additional family members. The existence of a core haplotype
shared among all carriers of the variant, independently of the cancer type, matching the conserved
region previously identified in the high-density SNP analysis, strongly corroborates a founder effect in
the CHEK2 variant c.349A>G.
Table 1. Microsatellite marker haplotypes of the 14 families carrying the CHEK2 variant c.349A>G.
Microsatellite Markers
Family D22S310 D22S689 CHEK2 D22S275 (Intragenic) D22S1150 D22S280
1 * 181 294 _ 159 216 211
2 * 183 294 _ 159 220 211
3 * 181 294 _ 159 216 205/211
4 * 179 294 _ 159 216/220 205
5 * 183/187 290/294 _ 159/163 218/220 205/211
6 185/189 294 _ 159/161 216/220 205
7 187 294 _ 159 216 211
8 185 294 _ 159 216 211
9 177/185 294/298 _ 159/161 220 209
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Table 1. Cont.
Microsatellite Markers
Family D22S310 D22S689 CHEK2 D22S275 (Intragenic) D22S1150 D22S280
10 179/187 294 _ 159/167 218/220 205/209
11 177/189 294 _ 159 216 205
12 185 294 _ 159 216 205/209
13 185 294 _ 159 220 209
14 177/181 294/302 _ 159 216/226 205/213
* Included in the high-density SNP haplotype analysis performed with the PRACTICAL samples. The shared core
haplotype associated with the variant is represented in bold.
3. Discussion
The CHEK2 gene plays a key role in DNA damage response [18], and although several germline
variants have been associated with increased cancer risk, particularly in breast cancer [22,29],
the mutational spectra, as observed in other cancer risk genes (e.g., BRCA1 and BRCA2 genes [30,31]),
varies widely among different populations. For instance, the CHEK2 variant c.1100delC, which has
been shown to increase breast cancer risk by 2-fold [29,32], is frequently found in northern European
populations, but is rare in southern European populations [33].
The CHEK2 variant c.349A>G was initially reported in two BRCA1/2-negative familial BrCa patients,
but no clear association was found with the disease at the time [34]. More recently, in a large-scale
case–control study this variant was associated with an increased risk of BrCa (OR 2.26), but not PrCa [22].
The pathogenic nature of the CHEK2 variant c.349A>G has been supported by both functional and
bioinformatic approaches, which suggested that this variant affects the forkhead-associated (FHA)
domain of CHEK2, resulting in lack of phosphorylation and oligomerisation, leading to reduced CHEK2
kinase activity and, ultimately, loss of DNA damage response [26,35–37].
To further increase our understanding of the contribution of the CHEK2 variant c.349A>G, which is,
to date, the only recurrent “likely pathogenic” variant in CHEK2 gene reported in the Portuguese
population [26], we completed the genotyping of a series of 462 cases with criteria for early-onset
and/or hereditary PrCa. The CHEK2 variant c.349A>G was more frequent in Portuguese PrCa patients
(n = 5) compared to controls (n = 1), with an odds-ratio suggesting a borderline association with the
disease. We sought to validate these findings with the large multicentre case–control PRACTICAL
consortium, which comprised 55,162 PrCa cases and 36,147 controls from 53 worldwide studies.
The CHEK2 variant c.349A>G was found in 52 PrCa cases and 18 controls of the PRACTICAL study,
providing clear evidence of its association with increased risk for PrCa. A 2- to 3-fold increased
PrCa risk has also been linked with other two well-studied CHEK2 founder variants, p.I157T and
c.1100delC, reinforcing the importance of CHEK2 as a moderate-penetrance PrCa susceptibility gene [21].
A similar modest increased risk has also been reported for men harbouring pathogenic variants in other
moderate-penetrance cancer genes, such as ATM [38], while a higher risk (up to 8-fold) is described
for carriers of alterations in high-penetrance cancer-predisposing genes, such as those associated
with hereditary breast and ovarian cancer syndrome (e.g., BRCA1 and, particularly, BRCA2) [39,40].
Noteworthy, a few founder variants prevalent in more genetically homogenous populations, such as
the HOXB13 G84E variant in Nordic populations, have been strongly associated with high risk (OR,
3.4) of PrCa [41].
Another key aspect revealed by these results is the widespread distribution of this variant,
which was found in carriers from 11 different countries, namely Australia, Belgium, Denmark, France,
Germany, Netherlands, Portugal, Spain, Sweden, the UK, and U.S. The recurrence of the CHEK2 variant
c.349A>G in, apparently, unrelated carriers from diverse populations could be due to independent
origin or carriers might share a common ancestor. We addressed this question by performing
haplotype analysis using high-density SNP data for all carriers available from the PRACTICAL dataset.
The conserved IBD haplotype flanking the CHEK2 variant c.349A>G in all carriers highly indicates
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a single common founder. Moreover, the haplotype reconstructed network, characterised with two
major haplotypes shared by distinct populations, suggests early recombination events splitting the
initial haplotype into distinct haplotypes in the founding population, most likely of Central European
origin, which were then carried as it rapidly spread. Noteworthy, a large conserved haplotype was
identified among all Scandinavian carriers, suggesting some degree of isolation after the introduction
of the variant into the population, whereas the UK carriers presented the smallest conserved haplotype,
most likely as result of this population history of extensive migration waves introducing distinct levels
of genetic differentiation into the region [42].
The conserved haplotype allied with the age estimates obtained by the two independent
mathematical approaches, the Bayesian and the likelihood-based methods, interestingly corroborated
an ancient founder origin for this variant, similar to what has been suggested for the CHEK2 variant
1100delC [43,44]. Furthermore, the age estimates obtained by DMLE+2.3 for the distinct populations
corroborate the likely origin of the variant in the Western/Central European region suggested by the
haplotype phylogeographic distribution, approximately between 2015 and 2500 years ago. According
to the results, it appears that the founder Western/Central population carrying distinct haplotypes,
subsequently spread to the Iberian Peninsula, UK, and Scandinavia regions. The variant age estimates
obtained for these populations are consistent with the European past population history, characterised
by extensive movements in the first millennium, the so-called Migration Period or the Barbarian
Invasions, which originated from the Central Europe region [45]. The haplotype analysis and age
estimates results obtained for the American and Australian carriers are also in line of a European
origin, most likely from British colonisers, who carried the European variant as they initially settled in
those regions (Figure 3) [46,47]. Nevertheless, since these populations also shared the haplotype with
other European populations that expanded to those continents, though to a lesser extent, we cannot
rule out other possible origins.
The estimates of the variant age may oscillate, since it depends heavily on the population growth
rates used, which historical evidence has shown to vary greatly over time. Therefore, in the present
work, we tried to account for this caveat, by employing two different population growth rate estimates.
However, caution is still needed when interpreting the age estimates, since the method relies on
strong assumptions that cannot be entirely verified [48]. On the other hand, it is important to take
into consideration that estimates based on historical population data may also contain errors that are
difficult to account. Nevertheless, the age estimates obtained in the present study were consistent
using different statistical approaches and are in line with the demographic history of the populations.
Taking into consideration that CHEK2 variants have been previously associated with other types
of cancer, such as breast cancer [22], we performed an additional microsatellite haplotype analysis
of all carriers available at IPO-Porto. The microsatellite analysis further corroborated the founder
nature of the CHEK2 variant c.349A>G, by revealing the existence of a core haplotype shared among
all 14 families carrying the variant, which is highly suggestive of a single mutational event rather
than multiple independent events trough time. Furthermore, the fact that the variant was found in
families with history of prostate, breast, gastric, and lung cancer supports CHEK2 as a multiorgan
cancer susceptibility gene, as previously suggested [49]. In fact, multiorgan susceptibly is characteristic
of other genes in the DNA damage-signalling pathway, as has been observed for BRCA1, BRCA2,
PALB2, and ATM genes [22,30,33,50–53].
4. Materials and Methods
4.1. Portuguese Early-Onset/Familial PrCa Sample Collection
To clarify the possible association of the CHEK2 variant c.349A>G with risk of early-onset/familial
PrCa, we extended the genetic screening performed in a previous study of 121 cases [26] to the complete
series of 462 cases with early-onset and/or familial PrCa [27]. As control data, we used the frequency
obtained for 710 controls, previously described [26].
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4.2. Genotyping of the CHEK2 Variant c.349A>G
Genotyping of the CHEK2 variant c.349A>G was performed, in the 341 cases not previously
screened, using the KASP technology genotyping (KBioscience, Herts, UK) with the KASP assay
primers previously reported [26].
4.3. Statistical Analysis
To evaluate the cancer-associated risk of the CHEK2 variant c.349A>G between cases and heathy
controls in the Portuguese series of early-onset/familial PrCa and in the samples from the PRACTICAL
Consortium, we estimated the odds ratios (ORs) and 95% confidence intervals (CIs) between carriers
and non-carriers for the different studies. All analyses were carried out using R.
4.4. Practical Sample Collection
For the high-density SNP haplotype analysis, we assembled genotype data obtained with the
Infinium OncoArray-500K BeadChip (Illumina) for 93,746 participants from 54 studies, as part of the
PRACTICAL consortium [4].
As this variant has only been reported in populations of European ancestral origin, we restricted
the dataset to 55,162 PrCa cases and 36,147 controls of European ancestry from 53 studies. From the
Portuguese early-onset/familial PrCa sample collection, 354 PrCa cases and 180 controls were included
in the PRACTICAL final dataset. The detailed sample collection is described in Table S4. All studies
were approved by the respective institutional review boards (38.010: Inherited predisposition to
prostate cancer), and informed consent was obtained for all participants.
4.5. OncoArray Genotyping and Quality Control
The OncoArray BeadChip includes a genome-wide backbone of 230,000 SNPs tagging most
common genetic variants, and a customised panel of 250,000 SNPs developed from previous GWAS
and fine-mapping studies of multiple cancer types, including PrCa [54]. The quality control of the
high-density SNP data from chromosome 22 was performed as previously described [4]. Briefly,
the procedure involved excluding SNPs with genotyping call rates <95% and failing Hardy–Weinberg
equilibrium, as well as checking for duplicates/first-degree relatives and population ancestry using
PLINK software [55]. We obtained a final dataset of 91,309 individuals and 8674 SNPs (Table S4),
from here on termed as the PRACTICAL dataset.
4.6. Identity-By-Descent Analysis and Phylogeographic Haplotype Reconstruction
We performed identity-by-descent (IBD) and haplotype analysis for all carriers of the CHEK2
variant c.349A>G in the PRACTICAL dataset. To obtain the population-matched control dataset for
the downstream analyses, we corrected for population structure by pruning the PRACTICAL dataset
to remove SNPs with excessive background linkage disequilibrium (pairwise genotypic correlation
r2 > 0.4) within a 50-SNP sliding window in 10 SNP steps, and applied principal components analysis
(PCA), with PLINK 1.9 and R software, to identify and exclude outliers (Figure S8). Then, we randomly
reduced the control data from the variant-carrying populations to obtain a final dataset with 100 control
individuals per population, except for the Netherlands (with only 65 controls).
High-density SNP data from chromosome 22 belonging to 1135 individuals (the 70 carriers
and 1065 non-carriers of the variant) were phased using BEAGLE 4.1 [56]. The existence of shared
haplotypes between carriers was assessed by IBD analysis using the Refined IBD algorithm [57].
The ibdtrim parameter was set to 25. The length of the shared haplotype was calculated by the distance
between the two last shared markers flanking the CHEK2 variant c.349A>G.
The phylogeographic patterns of variant-carrying haplotypes was determined by network
reconstruction based on the median joining algorithm [58] using PopART v1.7 [59].
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4.7. Age Estimation of the CHEK2 Variant c.349A>G
The SNPs flanking the margins of the different haplotypes identified by the IBD analysis,
where recombination events were likely to have occurred, were selected for the estimation of the variant
age using two statistical methods, the DMLE+2.3 [60] and ESTIAGE [61] software. The first method
was used to estimate the age of the variant in the different populations separately, as well on the
combined data of all populations to obtain an overall age estimate, whereas the second computational
approach was only used to estimate the overall combined age of the variant, due to limitations of
sample size per population group (as low as n = 4).
DMLE+2.3 uses a Bayesian method to compare differences in linkage disequilibrium between the
variant and flanking markers in variant carriers and non-carriers. The software employs a Markov chain
Monte Carlo (MCMC) method to generate the marginal posterior probability density of the variant age
based on the observed haplotypes in variant-carrying or normal chromosomes; map distances between
markers and variant site; population growth rates and an estimated proportion of the variant-carrying
chromosomes sampled.
The population growth rates were estimated as described before, using the formula: r(gen) =
ln
( Pp
P0
)
g ,
where r(gen) represents the population growth rate per generation, Pp is the estimated present population
size, P0 is the estimated size of the population at reference time, and g is the number of generations
between these two time points (assuming 25 years per generation) [48,62]. Historical and current
population size estimations were retrieved for all populations from Official Governmental demographic
information (Table S5). In addition, since the formula mentioned above assumes a constant exponential
population growth rate, which may not represent the history of the population, two rate estimates were
employed to account for possible fluctuations. The overall rate (r(gen)1) was calculated using the oldest
and the most recent population size estimates for each population, and the second, older rate (r(gen)2),
was estimated using only the population sizes of each population until the beginning of last century.
The proportion of variant-carrying chromosomes sampled was estimated according to the
frequency of the variant in each country (estimated based on the PRACTICAL dataset) and the number
of existing males as of 2017 (Table S5).
The ESTIAGE implements a likelihood-based method to estimate the age of the most recent
common ancestor (MRCA). We used allele frequencies obtained from control individuals and both
stepwise and equal variant models with a variant rate of ≈2 × 10−8 at each marker [63].
The genetic distances (cM) used in both software were obtained from the 1000 Genomes Phase
3 data [64], and positions absent from this map were interpolated.
4.8. Microsatellite Analysis
To extend the haplotype analysis to the carriers of the recurrent CHEK2 variant c.349A>G that
were not genotyped using the OncoArray DNA chip, we used five polymorphic microsatellite markers
flanking the gene, namely D22S310, D22S689, D22S275, D22S1150, and D22S280. A total of 14 probands
carrying the CHEK2 variant c.349A>G, which included an additional early-onset PrCa case not included
in the initial PrCa series, and 18 family members were genotyped. Primer sequences (except for the
D22S689 marker) were derived from the UCSC Genome Browser database (genome build 37) [65].
Primers for the D22S689 marker were designed using the online Primer-BLAST tool [66]. All markers
were assayed by PCR using fluorescently end-labelled primers and PCR products were run on a
3500 Genetic Analyzer together with the fluorescence labelled DNA fragment size standard 600-LIZ
(Thermo Fisher Scientific, Waltham, MA, USA). Haplotype construction was performed manually,
based on the genotypes obtained from probands and family members.
5. Conclusions
Our results provide evidence that the c.349A>G variant in the CHEK2 tumour-suppressor gene
is significantly associated with increased risk of PrCa. Moreover, haplotype analysis using both
Cancers 2020, 12, 3254 13 of 17
high-density SNP and microsatellite data, as well as variant age estimates, strongly support a founder
origin for this variant instead of multiple independent occurrences. The identification of founder
variants, such as the one here reported, may contribute for the development of more cost-efficient
screening strategies and counselling of high-risk families.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/11/3254/s1,
Figure S1: Age estimation of the CHEK2 variant c.349A>G in the Western/Central Europe populations (France,
Belgium, Germany, and Netherlands) using the DMLE 2.3 software, Figure S2: Age estimation of the CHEK2
variant c.349A>G in the Spanish carriers using the DMLE 2.3 software, Figure S3: Age estimation of the CHEK2
variant c.349A>G in the Portuguese carriers using the DMLE 2.3 software, Figure S4: Age estimation of the CHEK2
variant c.349A>G in the British carriers using the DMLE 2.3 software, Figure S5: Age estimation of the CHEK2
variant c.349A>G in the Scandinavian carriers (Denmark and Sweden) using the DMLE 2.3 software, Figure S6:
Age estimation of the CHEK2 variant c.349A>G in the Western/Central Europe populations (France, Belgium,
Germany, and Netherlands) using the DMLE 2.3 software, Figure S7: Age estimation of the CHEK2 variant
c.349A>G in U.S. carriers using the DMLE 2.3 software, Figure S8: PCA plots of all CHEK2 variant c.349A>G
carriers along with control individuals from the 11 variant-carrying populations (Australia, Belgium, Denmark,
France, Germany, Netherlands, Portugal, Spain, Sweden, UK, and USA) and China, the outlier population for
the PCA analysis, Table S1: Characterisation of the populations carrying the CHEK2 variant c.349A>G included
in the PRACTICAL consortium, Table S2: Overall age estimates of the CHEK2 variant c.349A>G, Table S3:
Age estimates of the CHEK2 variant c.349A>G in the different populations, Table S4: Characterisation of the
studies and participants from PRACTICAL consortium, Table S5: Population information for population growth
rates estimation. Supplementary Information: supplementary authors, additional funding and acknowledgments.
Author Contributions: Conception and design: A.B., P.P. and M.R.T.; analyses, A.B., P.P., M.P., A.P., M.C., M.P.S.,
C.S.; writing—original draft preparation, A.B., P.P. and M.R.T.; writing—revision of the manuscript, A.B., P.P.,
M.R.T., S.M., M.P., A.P., M.C., M.P.S., C.S., R.A.E., Z.K.-J., K.M., UKGPCS Collaborators, J.S., Y.W., N.P., J.B., APCB
BioResource, H.G., D.E.N., B.G.N.,C.M.T., M.C.S., A.W., D.A., C.A.H., R.C.T., J.L.S., L.A.M., C.M.L.W., S.F.N.,
S.K., S.I.B., A.S.K., O.C., K.D.S., C.C., E.M.G., J.Y.P., S.A.I., C.M., R.J.H., B.S.R., A.V., The IMPACT Study Steering
Committee and Collaborators, M.K., F.W., K.L.P., H.B., E.M.J., R.K., C.J.L., S.L.N., K.D.R., A.R., L.F.N., Canary PASS
Investigators, D.L., N.U., F.C., M.G.-D., P.A.T., M.J.R., The Profile Study Steering Committee, The PRACTICAL
Consortium; resources and data acquisition, S.M., R.A.E., Z.K.-J., K.M., UKGPCS Collaborators, J.S., Y.W., N.P., J.B.,
APCB BioResource, H.G., D.E.N., B.G.N.,C.M.T., M.C.S., A.W., D.A., C.A.H., R.C.T., J.L.S., L.A.M., C.M.L.W., S.F.N.,
S.K., S.I.B., A.S.K., O.C., K.D.S., C.C., E.M.G., J.Y.P., S.A.I., C.M., R.J.H., B.S.R., A.V., The IMPACT Study Steering
Committee and Collaborators, M.K., F.W., K.L.P., H.B., E.M.J., R.K., C.J.L., S.L.N., K.D.R., A.R., L.F.N., Canary PASS
Investigators, D.L., N.U., F.C., M.G.-D., P.A.T., M.J.R., The Profile Study Steering Committee, The PRACTICAL
Consortium. All authors have read and agreed to the published version of the manuscript.
Funding: We thank the funding support from IPO-Porto Research Center (CI-IPOP-16-2012) and from Fundação
para a Ciência e a Tecnologia (FCT; PEst-OE/SAU/ UI0776/2014 and PTDC/DTP-PIC/1308/2014). The following
authors were awarded with grants from FCT: PPa (UID/DTP/00776/2013/POCI-01-0145-FEDER-006868),
SM (SFRH/BD/71397/2010) and PPi (SFRH/BD/73719/2010). The PRACTICAL consortium (http://practical.icr.ac.uk/)
was supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework
Programme grant agreement n◦ 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357,
C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health
(NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative). Genotyping
of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci
Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease
Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565.
Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher). We would also like
to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign,
The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now PCUK), The Orchid Cancer
Appeal, Rosetrees Trust, The National Cancer Research Network UK, The National Cancer Research Institute
(NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute
of Cancer Research and The Royal Marsden NHS Foundation Trust, NIHR funding to the Manchester Biomedical
Research Centre and the Manchester Academic Health Sciences Centre.
Acknowledgments: We wish to thank all the patients and their relatives who took part in this study. We would also
like to thank Emmanuelle Genin for kindly providing the source code and documentation for the ESTIAGE software.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
Cancers 2020, 12, 3254 14 of 17
References
1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018:
GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.
2018, 68, 394–424. [CrossRef] [PubMed]
2. Bashir, M.N. Epidemiology of prostate cancer. Asian Pac. J. Cancer Prev. 2015, 16, 5137–5141. [CrossRef]
[PubMed]
3. Al Olama, A.A.; Kote-Jarai, Z.; Schumacher, F.R.; Wiklund, F.; Berndt, S.I.; Benlloch, S.; Giles, G.G.; Severi, G.;
Neal, D.E.; Hamdy, F.C.; et al. A meta-analysis of genome-wide association studies to identify prostate
cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum. Mol. Genet. 2013, 22,
408–415. [CrossRef]
4. Schumacher, F.R.; Al Olama, A.A.; Berndt, S.I.; Benlloch, S.; Ahmed, M.; Saunders, E.J.; Dadaev, T.;
Leongamornlert, D.; Anokian, E.; Cieza-Borrella, C.; et al. Association analyses of more than 140,000 men
identify 63 new prostate cancer susceptibility loci. Nat. Genet. 2018, 50, 928–936. [CrossRef] [PubMed]
5. Al Olama, A.A.; Kote-Jarai, Z.; Giles, G.G.; Guy, M.; Morrison, J.; Severi, G.; Leongamornlert, D.A.;
Tymrakiewicz, M.; Jhavar, S.; Saunders, E.; et al. Multiple loci on 8q24 associated with prostate cancer
susceptibility. Nat. Genet. 2009, 41, 1058–1060. [CrossRef] [PubMed]
6. Eeles, R.A.; Kote-Jarai, Z.; Al Olama, A.A.; Giles, G.G.; Guy, M.; Severi, G.; Muir, K.; Hopper, J.L.;
Henderson, B.E.; Haiman, C.A.; et al. Identification of seven new prostate cancer susceptibility loci through
a genome-wide association study. Nat. Genet. 2009, 41, 1116–1121. [CrossRef]
7. Eeles, R.; Goh, C.; Castro, E.; Bancroft, E.; Guy, M.; Al Olama, A.A.; Easton, D.; Kote-Jarai, Z. The genetic
epidemiology of prostate cancer and its clinical implications. Nat. Rev. Urol. 2014, 11, 18–31. [CrossRef]
8. Al Olama, A.A.; Kote-Jarai, Z.; Berndt, S.I.; Conti, D.V.; Schumacher, F.; Han, Y.; Benlloch, S.; Hazelett, D.J.;
Wang, Z.; Saunders, E.; et al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for
prostate cancer. Nat. Genet. 2014, 46, 1103–1109. [CrossRef]
9. Brechka, H.; Bhanvadia, R.R.; VanOpstall, C.; Griend, D.J.V. HOXB13 mutations and binding partners in
prostate development and cancer: Function, clinical significance, and future directions. Genes Dis. 2017, 4,
75–87. [CrossRef]
10. Ewing, C.M.; Ray, A.M.; Lange, E.M.; Zuhlke, K.A.; Robbins, C.M.; Tembe, W.D.; Wiley, K.E.; Isaacs, S.D.;
Johng, D.; Wang, Y.; et al. Germline mutations in HOXB13 and prostate-cancer risk. N. Engl. J. Med. 2012,
366, 141–149. [CrossRef] [PubMed]
11. Kote-Jarai, Z.; Mikropoulos, C.; Leongamornlert, D.A.; Dadaev, T.; Tymrakiewicz, M.; Saunders, E.J.; Jones, M.;
Jugurnauth-Little, S.; Govindasami, K.; Guy, M.; et al. Prevalence of the HOXB13 G84E germline mutation
in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.
Ann. Oncol. 2015, 26, 756–761. [CrossRef]
12. Breyer, J.P.; Avritt, T.G.; McReynolds, K.M.; Dupont, W.D.; Smith, J.R. Confirmation of the HOXB13 G84E
germline mutation in familial prostate cancer. Cancer Epidemiol. Biomark. Prev. 2012, 21, 1348–1353. [CrossRef]
13. Castro, E.; Eeles, R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J. Androl. 2012, 14, 409–414.
[CrossRef]
14. Maia, S.; Cardoso, M.; Paulo, P.; Pinheiro, M.; Pinto, P.; Santos, C.; Pinto, C.; Peixoto, A.; Henrique, R.;
Teixeira, M.R. The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained
for early-onset and/or familial prostate cancer. Fam. Cancer 2016, 15, 111–121. [CrossRef]
15. Petrovics, G.; Price, D.K.; Lou, H.; Chen, Y.; Garland, L.; Bass, S.; Jones, K.; Kohaar, I.; Ali, A.; Ravindranath, L.;
et al. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a
racially diverse patient population. Prostate Cancer Prostatic Dis. 2019, 22, 406–410. [CrossRef]
16. Grindedal, E.M.; Møller, P.; Eeles, R.; Stormorken, A.T.; Bowitz-Lothe, I.M.; Landrø, S.M.; Clark, N.; Kvåle, R.;
Shanley, S.; Mæhle, L. Germline mutations in mismatch repair genes associated with prostate cancer.
Cancer Epidemiol. Biomark. Prev. 2009, 18, 2460–2467. [CrossRef]
17. Guedes, L.B.; Antonarakis, E.S.; Schweizer, M.T.; Mirkheshti, N.; Almutairi, F.; Park, J.C.; Glavaris, S.;
Hicks, J.; Eisenberger, M.A.; De Marzo, A.M.; et al. MSH2 loss in primary prostate cancer. Clin. Cancer Res.
2017, 23, 6863–6874. [CrossRef]
18. Seppälä, E.H.; Ikonen, T.; Mononen, N.; Autio, V.; Rökman, A.; Matikainen, M.P.; Tammela, T.L.J.; Schleutker, J.
CHEK2 variants associate with hereditary prostate cancer. Br. J. Cancer 2003, 89, 1966–1970. [CrossRef]
Cancers 2020, 12, 3254 15 of 17
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